Aims and Scope
Expert Review of Anticancer Therapy is a monthly peer-reviewed medical journal covering all clinical aspects of cancer therapy. It was established in 2001 and is published by Taylor & Francis under the academic publishing division of Informa. The current Editor-in-Chief is Gertjan J L Kaspers who is Head of Pediatric Oncology at VU University Medical Center Amsterdam. According to Journal Citation Reports, the journal has a 2019 impact factor of 3.573.
Key Metrics
6.7
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
79
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
Q2
Oncology
SJR
- Q2 Oncology
- Q2 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.08
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
5 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
21%
4 to 6 months
50%
7 to 9 months
22%
Above 9 months
7%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Cancer
- Lung cancer
- Breast cancer
- Lymph node
- Systematic review
- Immunotherapy
- Chemoradiotherapy
- Hepatocellular carcinoma
- Neuroendocrine tumors
- Toxicity
- Epidermal growth factor receptor
- Pediatric acute myeloid leukemia
- Thyroid cancer
- Trastuzumab emtansine
- Prostate cancer
- Clinical trial
- Systemic therapy
- Platinum
- Tumor microenvironment
- Toxicity profile
Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Expert Review of Anticancer Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
NRF2/KEAP1 signaling inhibitors in gynecologic cancers
- 9 Dec 24
- Expert Review of Anticancer Therapy
-
Full paper
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies
- 8 Dec 24
- Expert Review of Anticancer Therapy
-
Full paper
Arguments for and against extending the interval between colonoscopies following negative results in colorectal cancer screening
- 1 Dec 24
- Expert Review of Anticancer Therapy
-
Full paper
Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis
- 28 Nov 24
- Expert Review of Anticancer Therapy
-
Full paper
Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients
- 17 Nov 24
- Expert Review of Anticancer Therapy
-
Full paper
Statin use and ovarian cancer outcomes
- 11 Nov 24
- Expert Review of Anticancer Therapy
Scite analysis
Powered by scite_
3.5k articles received 43.6k citations see all
- 745 Supporting
- 41,654 Mentioning
- 88 Contrasting
Editorial notices
- 1 Retractions
- 0 Withdrawals
- 6 Corrections
- 6 Errata
- 0 Expression of Concern
FAQs
How long has Expert Review of Anticancer Therapy been actively publishing?
Expert Review of Anticancer Therapy has been in operation since 2000 till date.
What is the publishing frequency of Expert Review of Anticancer Therapy ?
Expert Review of Anticancer Therapy published with a Monthly frequency.
How many articles did Expert Review of Anticancer Therapy publish last years ?
In 2023, Expert Review of Anticancer Therapy published 121 articles.
What is the eISSN & pISSN for Expert Review of Anticancer Therapy ?
For Expert Review of Anticancer Therapy,eISSN is 1744-8328 and pISSN is1473-7140.
What is Citescore for Expert Review of Anticancer Therapy ?
Citescore for Expert Review of Anticancer Therapy is 6.7.
What is H index for Expert Review of Anticancer Therapy ?
H index for Expert Review of Anticancer Therapy is 79.
What is SNIP score for Expert Review of Anticancer Therapy ?
SNIP score for Expert Review of Anticancer Therapy is 1.08.
What is the SJR for Expert Review of Anticancer Therapy ?
SJR for Expert Review of Anticancer Therapy is Q2.
Who is the publisher of Expert Review of Anticancer Therapy ?
TAYLOR & FRANCIS LTD is the publisher of Expert Review of Anticancer Therapy.